

William B. Kielbasa, Ph.D.

Principal Research Scientist, Global PK/PD, Eli Lilly and Company

Dr. Kielbasa received a doctorate in pharmaceutical sciences from the University at Buffalo, the State University of New York, in May 2000 and subsequently joined Lilly as a Senior Scientist in Drug Disposition in June 2000. Dr. Kielbasa has provided strong scientific leadership on numerous program teams as the lead preclinical and clinical PK/PD scientist. He implemented novel and effective PK/PD modeling and simulation clinical development plans, primarily in the neuroscience and endocrine therapeutic areas, to understand the dose – exposure – biomarker response relationships of clinical candidates and marketed compounds. Dr. Kielbasa has an interest in studying the neuropharmacokinetics of drugs in animals using brain microdialysis to support clinical biomarker and dose selection strategies. His work significantly contributed to the advancement of drugs from lead optimization to clinical development, including Phase 3.

Literature References

Kielbasa W, Stratford RE. Exploratory Translational Modeling Approach in Drug Development to Predict Human Brain Pharmacokinetics and Pharmacologically Relevant Clinical Doses. *Drug Metab Dispos.* 2012 Jan 27.

Tauscher J, Kielbasa W, Iyengar S, Vandenhende F, Peng X, Mozley D, Gehlert DR, Marek G. Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. *Eur Neuropsychopharmacol.* 2010 Feb;20(2):80-7

Dubé S, Dellva MA, Jones M, Kielbasa W, Padich R, Saha A, Rao P. A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. *J Psychiatr Res.* 2010 Apr;44(6):356-63

Kielbasa W, Kalvass JC, Stratford RE. 2008. Microdialysis Evaluation of Atomoxetine Brain Penetration and Central Nervous System Pharmacokinetics in Rats. *Drug Metab Dispos.* 2009 Jan;37(1):137-42

George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, Peng X, Kielbasa W, Rawlings R, Brandt JE, Gehlert DR, Tauscher JT, Hunt SP, Hommer D, Heilig M. Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. *Science.* 2008 Mar 14;319(5869):1536-9.

Seneca N, Gulyása B, Varronec A, Schoua M, Tauscher J, Vandenhende F, Kielbasa W, Farde L, Innis R and Halldin C. Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: A PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2. *Psychopharmacology.* 2006 Sep; 188(1):119-27

Kielbasa W, Fung HL. Systemic biochemical effects of inhaled NO in rats: increased expressions of NOS III, nitrotyrosine-, and phosphotyrosine-immunoreactive proteins in liver and kidney tissues. *Nitric Oxide.* 2001 Dec;5(6):587-94

Kielbasa W, Fung HL. Nitrite inhalation in rats elevates tissue NOS III expression and alters tyrosine nitration and phosphorylation. *Biochem Biophys Res Commun.* 2000 Aug 28;275(2):335-42

Kielbasa W, Fung HL. Relationship between pharmacokinetics and hemodynamic effects of inhaled isobutyl nitrite in conscious rats. *AAPS PharmSci.* 2000;2(2):E11

Kielbasa W, Fung HL. 2000. Pharmacokinetics of a model organic nitrite inhalant and its alcohol metabolite in rats. *Drug Metab Dispos.* 2000 Apr;28(4):386-91

Kielbasa W, Bauer JA, Fung HL. Analysis of isobutyl nitrite inhalant in rat and human blood: application for pharmacokinetic investigations. *J Chromatogr B Biomed Sci Appl.* 1999 Oct 29;734(1):83-9